Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

SII and Univercells Partner to Make Personalized Oncology Affordable for Masses

NextEdge Admin

12 Apr 2024

3 min 28 sec

In a groundbreaking collaboration announcement, Serum Institute of India (SII), the world’s largest vaccine manufacturer, has partnered with Univercells, a pioneering biotech company based in Belgium, to revolutionize access to personalized cancer care. This alliance aims to democratize advanced treatment options, making them available to millions worldwide.

Currently, innovative personalized treatments like novel cancer vaccines and specialized immunotherapies are limited to a privileged few due to their time-consuming and costly development process. Moreover, stringent regulatory constraints on genetic material transfer and manufacturing restrict their availability to only a handful of nations. The SII and Univercells collaboration seeks to tackle these obstacles, intending to tap into the global cancer care market.

Dr. Umesh Shaligram, SII’s Executive Director of R&D, expressed enthusiasm about the partnership, emphasizing its potential to enhance cancer care accessibility, particularly in low- and middle-income countries (LMICs). He highlighted their focus on developing a unique point-of-care cancer treatment using mRNA in conjunction with Recombinant BCG (VPM1002), aiming to address high relapse rates, especially in late-stage cancer patients.

José Castillo, Univercells’ Chief Technology Officer & Co-founder, outlined the revolutionary aspects of their technology, which significantly reduces the time and cost involved in creating personalized therapeutics while maintaining quality standards. By redesigning the manufacturing process, they anticipate saving up to 90% in production costs compared to traditional methods.

Crucially, Univercells’ technology enables small-scale, local production, empowering countries and hospitals to offer personalized therapies locally. Leveraging SII’s extensive global presence, these therapies can reach patients across Europe, India, and Africa, thanks to SII’s widespread operations.

Looking ahead, both Univercells and SII aim to expedite the journey of new medicines to patients. Currently, the lengthy process from patenting to patient use averages around 15 years in the UK. However, they aspire to compress this timeline to just 3 years, leveraging automation and stringent quality standards to overcome regulatory barriers and deliver breakthrough therapies to patients in a timely manner.

This collaboration represents a significant step towards democratizing cancer care, bringing hope to millions of patients worldwide and potentially revolutionizing the pace of medical innovation in the fight against cancer.